Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Dacarbazine/adverse effects"'
Autor:
Christof M. Kramm, Maria Wiese, Dagmar Dilloo, Gerrit H. Gielen, Pablo Hernáiz Driever, Matthias Dürken, Selim Corbacioglu, Michael Karremann, Marion Hoffmann, Wolfram Scheurlen, Andreas Beilken, André O. von Bueren, Andreas E. Kulozik, Nadja Krämer
Publikováno v:
European Journal of Cancer, Vol. 81 (2017) pp. 1-8
Background Temozolomide (TMZ) is widely used in high-grade glioma (HGG). There is a major concern of treatment-induced secondary haematological malignancies (SHMs). Due to the poor overall survival of HGG patients, the true incidence is yet elusive.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce5a64fa25885c70b3633adf75e093dd
https://doi.org/10.1016/j.ejca.2017.04.023
https://doi.org/10.1016/j.ejca.2017.04.023
Autor:
Jay-Jiguang Zhu, Manmeet Ahluwalia, Sun Ha Paek, Steven Brem, Francesco Di Meco, David M. Steinberg, Zvi Ram, Steven A. Toms, Chae-Yong Kim, Garth Nicholas, David Tran, Andreas F. Hottinger, Andrew A. Kanner, Ahmed Idbaih, Giuseppe Stragliotto, Gitit Lavy-Shahaf, Michael Weller, Eilon D. Kirson, Frank S. Lieberman, Uri Weinberg, Monika E. Hegi, Yoram Palti, Sophie Taillibert, Roger Stupp, H Hirte, William L. Read, Benoit Lhermitte, Jordi Burna, Karen Fink
Publikováno v:
JAMA, vol. 318, no. 23, pp. 2306-2316
Tumor-treating fields (TTFields) is an antimitotic treatment modality that interferes with glioblastoma cell division and organelle assembly by delivering low-intensity alternating electric fields to the tumor. To investigate whether TTFields improve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a47c8577143871dbe41d3b7c006ef05
https://serval.unil.ch/notice/serval:BIB_868908B10151
https://serval.unil.ch/notice/serval:BIB_868908B10151
Autor:
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, Van Den Weyngaert D, Kaendler S, Krauseneck P, Vinolas N, Villa S, Wurm RE, Maillot MHB, Spagnolli F, Kantor G, Malhaire JP, Renard L, De Witte O, Scandolaro L, Vecht CJ, Maingon P, Lutterbach J, Kobierska A, Bolla M, Souchon R, Mitine C, Tzuk-Shina T, Kuten A, Haferkamp G, de Greve J, Priou F, Menten J, Rutten I, Clavere P, Malmstrom A, Jancar B, Newlands E, Pigott K, Twijnstra A, Chinot O, Reni M, Boiardi A, Fabbro M, Campone M, Bozzino J, Frenay M, Gijtenbeek J, Delattre JY, De Paula U, Hanzen C, Pavanato G, Schraub S, Pfeffer R, Soffietti R, Kortmann RD, Taphoorn M, Torrecilla JL, Grisold W, Huget P, Forsyth P, Fulton D, Kirby S, Wong R, Fenton D, Cairncross G, Whitlock P, Burdette-Radoux S, Gertler S, Saunders S, Laing K, Siddiqui J, Martin LA, Gulavita S, Perry J, Mason W, Thiessen B, Pai H, Alam ZY, Eisenstat D, Mingrone W, Hofer S, Pesce G, Dietrich PY, Thum P, Baumert B, Ryan G
Publikováno v:
New England Journal of Medicine, vol. 352, no. 10, pp. 987-96
New England Journal of Medicine, 352(10), 987-996. Massachussetts Medical Society
New England Journal of Medicine, 352(10), 987-996. Massachussetts Medical Society
BACKGROUND: Glioblastoma, the most common primary brain tumor in adults, is usually rapidly fatal. The current standard of care for newly diagnosed glioblastoma is surgical resection to the extent feasible, followed by adjuvant radiotherapy. In this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf112f90a929a68afabcd377cbf792ea
https://doi.org/10.1056/NEJMoa043330
https://doi.org/10.1056/NEJMoa043330